Navigation Links
Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results
Date:11/6/2007

CAMBRIDGE, Mass., Nov. 6 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases, today reported unaudited financial results for the third quarter and nine months ended September 30, 2007. At September 30, 2007, Idenix's cash, cash equivalents and marketable securities totaled approximately $136.5 million.

For the third quarter ended September 30, 2007, Idenix reported total revenues of $10.9 million, compared with total revenues of $19.6 million in the third quarter of 2006. Total revenues for the third quarter of 2007 consist of reimbursement by Novartis Pharma AG of expenses incurred by Idenix in connection with the development of Tyzeka(R)/Sebivo(R) (telbivudine), valtorcitabine and valopicitabine, Idenix's product and product candidates for the treatment of hepatitis B virus (HBV) and hepatitis C virus (HCV), respectively, and the amortization of the up-front fees received by Idenix in connection with Novartis' license of telbivudine, valtorcitabine and valopicitabine and product sales of Tyzeka/Sebivo. Idenix reported a net loss of $30.5 million, or a loss of $0.54 per basic and diluted share for the third quarter ended September 30, 2007, compared to a net loss of $19.7 million, or a loss of $0.35 per basic and diluted share for the third quarter ended September 30, 2006. Included in the net loss for the third quarter ended September 30, 2007 was a $6.4 million restructuring charge primarily related to severance costs and impairment of certain fixed assets related to the transition of commercialization, development and manufacturing activities for telb
'/>"/>

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/22/2014)... Jersey Institute of Technology (NJIT) today to join ... of the New Jersey Innovation Institute (NJII), an ... business innovation through the leveraging of industry, government, ... Cory Booker, Panasonic Corp. of North America Chairman ... Kim Guadagno, New Jersey Secretary of Higher Education ...
(Date:4/22/2014)... DALLAS April 22, 2014 Researchers at UT ... people suffering from depression . , A ... major mechanism by which ghrelin (a hormone with natural ... identified a potentially powerful new treatment for depression in ... , The study, published online in April,s ...
(Date:4/22/2014)... Washington, DC (April 22, 2014) The International ... May 22-26 in Seattle, Washington. The theme of ... life" means in a networked and digital society. ... and attended by over 2,200 Communication scholars representing ... largest scholarly international communication conference in the world. ...
(Date:4/22/2014)... 22 April 2014. The latest scientific advances and emerging ... Failure 2014, the main annual meeting of the Heart ... (ESC). Journalists will also hear breaking news on acute ... Heart Failure, which is part of the main congress. ... Athens, Greece, at the Megaron Athens International Conference Centre ...
(Date:4/22/2014)... ARBOR, Mich. Nearly 7 in 10 Americans ... a new national survey by researchers at the University ... with children under the age of 18 at home, ... more likely than other adults to support universal coverage ... appear in the Journal of the American Medical ...
Breaking Medicine News(10 mins):Health News:Government and industry leaders herald launch of NJIT's New Jersey Innovation Institute 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 3Health News:International Communication Association to hold Annual Conference in Seattle, Washington 2Health News:The world's largest heart failure congress 2Health News:The world's largest heart failure congress 3Health News:More than two-thirds of Americans support mandated coverage of birth control in health plans 2
... 11, 2008 The American Cancer Society announced today ... for Exemplary Leadership in Tobacco Control. The awards are ... L. Terry, M.D., who led the landmark 1964 Surgeon ... and other illnesses. Dr. Terry,s courageous and groundbreaking work ...
... Deanna Vankessel, author of the recently published G lobal Markets ... to offer extensive expertise on the recent FDA premarket approval recommendation of ... , , MRG,s Deanna Vankessel is available ... , How ...
... Begin in December - , , ... Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE ), ... neratinib (HKI-272) in women with advanced HER-2-positive breast cancer. These ... breast cancer positive for the ErbB-2 receptor (also known as HER-2 ...
... Health Company (NYSE Alternext: FHC) has announced that the U.S. ... Committee has unanimously voted that the company,s second-generation female condom, ... , , The Advisory ... condition that the FC2 Female Condom,s instructions for use continue ...
... with ribavirin for previously untreated children with chronic hepatitis ... , KENILWORTH, N.J., Dec. 12 Schering-Plough ... the U.S. Food and Drug Administration (FDA) has granted ... USP) combination therapy for use in previously untreated patients ...
... Case Medical Center in conjunction with Sodexo Health Care Services ... 24/6 unit, the original certified kosher hot food vending machine. ... in the state of Ohio, offering patients and their caregivers ... , University Hospitals prides itself ...
Cached Medicine News:Health News:American Cancer Society recognizes international tobacco control leaders 2Health News:American Cancer Society recognizes international tobacco control leaders 3Health News:American Cancer Society recognizes international tobacco control leaders 4Health News:American Cancer Society recognizes international tobacco control leaders 5Health News:American Cancer Society recognizes international tobacco control leaders 6Health News:Millennium Research Group Analyst Available to Comment on FDA's Premarket Approval Recommendation of Genzyme Biosurgery's Synvisc Single-Injection Product for the Knee 2Health News:Wyeth Announces Positive Data from Phase 2 Study of Neratinib in Advanced HER-2-Positive Breast Cancer 2Health News:Wyeth Announces Positive Data from Phase 2 Study of Neratinib in Advanced HER-2-Positive Breast Cancer 3Health News:Wyeth Announces Positive Data from Phase 2 Study of Neratinib in Advanced HER-2-Positive Breast Cancer 4Health News:FDA Advisory Committee Votes Unanimously that FC2 Female Condom(R) is Approvable 2Health News:FDA Advisory Committee Votes Unanimously that FC2 Female Condom(R) is Approvable 3Health News:FDA Advisory Committee Votes Unanimously that FC2 Female Condom(R) is Approvable 4Health News:FDA Advisory Committee Votes Unanimously that FC2 Female Condom(R) is Approvable 5Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 2Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 3Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 4Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 5Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 6Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 7Health News:University Hospitals Case Medical Center Installs First Hot Kosher Vending Machine 2Health News:University Hospitals Case Medical Center Installs First Hot Kosher Vending Machine 3
(Date:1/15/2014)...  Echo Therapeutics, Inc. (Nasdaq: ECTE ) ("Echo"), ... as a non-invasive, wireless continuous glucose monitoring system, today ... and Interim CEO of Echo Therapeutics, will present at ... Mr. Doman will make a corporate ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Worldwide Analysis http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Insulin Pumps are ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Drug Delivery Systems -- Focus on End ... STUDY OBJECTIVES A drug ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18
... ... ... ... ...
... ... ... ... ...
Cached Medicine Technology:InteractElsevier Delivers 3-D Interactive Anatomy Learning Tools 2InteractElsevier Delivers 3-D Interactive Anatomy Learning Tools 3InteractElsevier Delivers 3-D Interactive Anatomy Learning Tools 4InteractElsevier Delivers 3-D Interactive Anatomy Learning Tools 5InteractElsevier Delivers 3-D Interactive Anatomy Learning Tools 6InteractElsevier Delivers 3-D Interactive Anatomy Learning Tools 7InteractElsevier Delivers 3-D Interactive Anatomy Learning Tools 8InteractElsevier Delivers 3-D Interactive Anatomy Learning Tools 9InteractElsevier Delivers 3-D Interactive Anatomy Learning Tools 10Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010 2Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010 3Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010 4Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010 5Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010 6Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010 7Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010 8Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010 9Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010 10Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010 11Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010 12Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010 13Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010 14Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010 15Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010 16Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010 17Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010 18Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010 19Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010 20Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010 21Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010 22Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010 23Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010 24Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010 25Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010 26
MDI will work with your facility to determine the best interim lab to fit your needs and your site....
... large number of mobile, modular and transportable ... fleet. The labs are typically leased to ... The Cath Lab Leasing Company allows hospitals ... upgrading existing equipment, initiating a new service ...
... PowerSuite holmium laser combines excellent cutting, ... virtually bloodless procedures. It is also ... gall bladder stones of all compositions, ... tool. Because its laser light is ...
... technology has allowed for perfecting mini-invasive endoscopic ... various pathologies with a considerable social impact. ... reducing the post-operatory times and represents a ... in all hospital structures.,DEKAs family of Nd:YAG ...
Medicine Products: